priors.science/reviews/chronic-pain-pharmacotherapy

Chronic Pain Pharmacotherapy

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
Weeklyre-scored against new papers
0 Established · 3 Likely · 9 Uncertain · 4 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StablePregabalin reduces pain scores in diabetic peripheral neuropathyGabLikely81%
StableDuloxetine reduces pain and disability in diabetic neuropathic painAntLikely73%
StableSNRIs reduce pain scores in fibromyalgiaAntLikely67%
StableCannabis cognitive adverse effectsCanUncertain62%
StableTapentadol over oxycodone in neuropathyOpdUncertain57%
StableOpioids induce hyperalgesiaOpdUncertain50%
StableGabapentinoids in non-neuropathic painGabUncertain45%
StableBuprenorphine vs full-agonist opioidsOpdUncertain44%
StableGabapentin vs pregabalin efficacyGabUncertain42%
StableLow-dose naltrexone in fibromyalgiaNovUncertain42%
StableMedical cannabis for chronic painCanUncertain40%
StableTapering improves pain outcomesOpdDoubtful32%
StableKetamine-assisted opioid taperingNovDoubtful30%
StableTHC-dominant cannabis reduces pain more than CBD-only formulationsCanDoubtful25%
StableDuloxetine plus pregabalin in neuropathyAntDoubtful21%
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic